Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.87 -0.38 (-2.37%)
Streaming Delayed Price Updated: 3:13 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Takeda Announces Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Wednesday Market Coverage ↗
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
News headline image
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause ↗
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Bitcoin Futures Arrive ↗
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
News headline image
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs ↗
Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue... 
Via Benzinga
News headline image
Calithera Buys Two Oncology Candidates From Takeda For $45M ↗
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).... 
Via Benzinga
News headline image
Chinese Growth Level ↗
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
News headline image
Europe's Unicorns ↗
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
News headline image
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings ↗
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to... 
Via Benzinga
News headline image
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Perfumes Of Arabia ↗
Downtrends do eventually run out of pessimistic steam, but it can take a while. 
Via Talk Markets
News headline image
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today ↗
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
News headline image
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials ↗
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the... 
Via Benzinga
News headline image
Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests ↗
Takeda Pharmaceutical was testing a drug called TAK-994 in narcolepsy patients. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
News headline image
Takeda Discontinues Two Mid-Stage Narcolepsy Trials ↗
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin... 
Via Benzinga
News headline image
Takeda Provides Update on TAK-994 Clinical Program
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA... 
Via Benzinga
News headline image
September Ends ↗
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.